An FDA-approved medication already used to treat people who have type 2 diabetes and chronic kidney disease may also help ...

The FDA’s recent approval of OZEMPIC highlights the expanding use of GLP-1 drugs beyond diabetes and weight management. Novo Nordisk’s blockbuster medication has gained another label expansion, now ...

Lupin and its alliance partner Natco received clearance from the FDA for bosentan tablets for oral suspension, 32 mg, which ...

AstraZeneca will gain full rights for roxadustat in China where it is approved to treat anaemia seen with chronic kidney ...

Sotagliflozin, a drug for diabetes and kidney disease, offers significant protection against heart attacks and strokes by ...

Novo Nordisk alleges Singaporean biotech KBP Biosciences made misleading statements before the two firms inked a licensing ...

The FDA has granted a speedy review of Eli Lilly ... to reduce the risk of renal failure and cardiovascular death in people with chronic kidney disease (CKD). The new indication could unlock ...

AstraZeneca is paying $160 million for FibroGen’s China business, giving the U.K.-based Big Pharma the regional rights to ...

Unicycive Therapeutics (UNCY) announced the publication of preclinical data describing the benefits of combination treatment of oxylanthanum ...

A team of researchers, led by one of Indian origin, has found that a drug recently approved by the US Food and Drug ...

Bayer's big investment in time and money on the development of finerenone for chronic kidney disease (CKD) in diabetics has paid off with an FDA approval, although it could face stiff competition ...

While conducting the study, the researchers tracked data from more than 10,000 patients who presented with type 2 diabetes, ...